CO6440515A2 - Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b - Google Patents

Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b

Info

Publication number
CO6440515A2
CO6440515A2 CO11150255A CO11150255A CO6440515A2 CO 6440515 A2 CO6440515 A2 CO 6440515A2 CO 11150255 A CO11150255 A CO 11150255A CO 11150255 A CO11150255 A CO 11150255A CO 6440515 A2 CO6440515 A2 CO 6440515A2
Authority
CO
Colombia
Prior art keywords
antibodies
compositions
methods
directed
complement protein
Prior art date
Application number
CO11150255A
Other languages
English (en)
Inventor
Bijan Etemad-Gilbertson
Braydon Charles Guild
Yong-In Kim
Ingo Klagge
Alexandra Kraus
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO6440515A2 publication Critical patent/CO6440515A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de enlace de antígeno de los mismos, que se enlazan a la proteína de complemento C3b tanto humana como de cinomolgo, así como a composiciones y métodos de uso de los mismos.
CO11150255A 2009-05-06 2011-11-04 Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b CO6440515A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06

Publications (1)

Publication Number Publication Date
CO6440515A2 true CO6440515A2 (es) 2012-05-15

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11150255A CO6440515A2 (es) 2009-05-06 2011-11-04 Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b

Country Status (22)

Country Link
US (1) US20100291106A1 (es)
EP (1) EP2427491A2 (es)
JP (1) JP2012525829A (es)
KR (1) KR20120088551A (es)
CN (1) CN102459334A (es)
AR (1) AR076655A1 (es)
AU (1) AU2010252156A1 (es)
CA (1) CA2760757A1 (es)
CL (1) CL2011002756A1 (es)
CO (1) CO6440515A2 (es)
EA (1) EA201101593A1 (es)
EC (1) ECSP11011445A (es)
IL (1) IL216061A0 (es)
MA (1) MA33402B1 (es)
MX (1) MX2011011754A (es)
PE (1) PE20120899A1 (es)
SG (1) SG175432A1 (es)
TN (1) TN2011000528A1 (es)
TW (1) TW201043638A (es)
UY (1) UY32612A (es)
WO (1) WO2010136311A2 (es)
ZA (1) ZA201107551B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
JP5871798B2 (ja) 2009-07-02 2016-03-01 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 肝再生を刺激する方法
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
EP2569332B1 (en) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Improved complement receptor 2 (cr2) targeting groups
KR20130036276A (ko) 2010-06-22 2013-04-11 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 보체 결합 3의 C3d 조각에 대한 항체들
CA2821067C (en) * 2010-11-29 2019-06-04 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
WO2013152024A1 (en) * 2012-04-03 2013-10-10 Novelmed Therapeutics, Inc Humanized and chimeric anti-factor c3 antibodies and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
AU2013302441B2 (en) 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
AU2013334229B2 (en) * 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
CN104936618A (zh) * 2012-11-29 2015-09-23 拜尔健康护理有限责任公司 针对活化蛋白c的人源化单克隆抗体及其用途
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
KR102192596B1 (ko) 2013-08-07 2020-12-18 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
EP3054965B1 (en) * 2013-10-07 2021-04-14 Massachusetts Eye & Ear Infirmary Anti-factor d antibody for use in preventing or reducing retinal detachment
EP3086809A4 (en) * 2013-12-24 2017-11-29 NovelMed Therapeutics, Inc. Compositions and methods of treating ocular diseases
BR112016019825A2 (pt) 2014-02-27 2017-10-17 Allergan Inc anticorpos do fator bb do complemento
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
SG11202008897SA (en) 2018-04-03 2020-10-29 Ngm Biopharmaceuticals Inc C3-binding agents and methods of use thereof
EP4257602A3 (en) * 2018-06-11 2023-12-27 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
AU2022237648A1 (en) * 2021-03-19 2023-10-19 Elpis Biopharmaceuticals Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof
KR20230105972A (ko) * 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
US20240132617A1 (en) * 2022-09-20 2024-04-25 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b antibodies
WO2024108529A1 (en) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Properdin binding protein and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK1287364T3 (da) * 2000-04-29 2009-03-02 Univ Iowa Res Found Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
JP2008521870A (ja) * 2004-12-02 2008-06-26 ドマンティス リミテッド 抗ｉｌ−１ｒ１単一ドメイン抗体および治療使用
KR101472250B1 (ko) * 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
MX2009013082A (es) * 2007-06-07 2010-01-15 Genentech Inc Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares

Also Published As

Publication number Publication date
EA201101593A1 (ru) 2012-06-29
CL2011002756A1 (es) 2012-03-23
MA33402B1 (fr) 2012-07-03
TN2011000528A1 (en) 2013-05-24
AR076655A1 (es) 2011-06-29
UY32612A (es) 2010-12-31
WO2010136311A2 (en) 2010-12-02
IL216061A0 (en) 2012-01-31
CN102459334A (zh) 2012-05-16
ZA201107551B (en) 2012-07-25
MX2011011754A (es) 2011-11-29
SG175432A1 (en) 2011-12-29
KR20120088551A (ko) 2012-08-08
AU2010252156A1 (en) 2011-11-10
ECSP11011445A (es) 2012-01-31
EP2427491A2 (en) 2012-03-14
TW201043638A (en) 2010-12-16
US20100291106A1 (en) 2010-11-18
CA2760757A1 (en) 2010-12-02
JP2012525829A (ja) 2012-10-25
WO2010136311A3 (en) 2011-05-26
PE20120899A1 (es) 2012-08-03

Similar Documents

Publication Publication Date Title
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CY1118014T1 (el) Aνti-il-23 αντισωματα
CO7250445A2 (es) Proteínas de unión a antígeno st2
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
BR112013021562A2 (pt) anticorpos para cd70
CR20170262A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
CR20110358A (es) Proteinas de enlace de miostatina
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201400579A1 (ru) Антитела к il-36r
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
EA201490677A1 (ru) Связывающие антиген cd27l белки
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
UY37030A (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
EA201291065A1 (ru) Антитела против vla-4
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
EA201500502A1 (ru) Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3
BR112013007514A2 (pt) anticorpo isolado, uso da composição e método
CO6721048A2 (es) Anticuerpos que se unen a notum pectinacetilesterasa
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
AR123070A2 (es) Anticuerpos anti-il-23

Legal Events

Date Code Title Description
FC Application refused